Evidence map›Paper›PMID 36344871›Full record

ReviewDrug delivery and translational research2023

Multifunctional nanomedicine strategies to manage brain diseases.

Paulo Faria, Catarina Pacheco, Rui Pedro Moura, Bruno Sarmento, Cláudia Martins

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drug delivery and translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Recent progress of nanomedicine in the treatment of Alzheimer's disease.Frontiers in cell and developmental biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Paulo FariaI3S-Instituto de Investigação e Inovação em Saúde, Universidade Do Porto, Rua Alfredo Allen 208, 4200-135, Porto, Portugal.
Catarina PachecoI3S-Instituto de Investigação e Inovação em Saúde, Universidade Do Porto, Rua Alfredo Allen 208, 4200-135, Porto, Portugal.
Rui Pedro MouraI3S-Instituto de Investigação e Inovação em Saúde, Universidade Do Porto, Rua Alfredo Allen 208, 4200-135, Porto, Portugal.
Bruno SarmentoI3S-Instituto de Investigação e Inovação em Saúde, Universidade Do Porto, Rua Alfredo Allen 208, 4200-135, Porto, Portugal. bruno.sarmento@i3s.up.pt.
Cláudia MartinsI3S-Instituto de Investigação e Inovação em Saúde, Universidade Do Porto, Rua Alfredo Allen 208, 4200-135, Porto, Portugal. claudia.martins@i3s.up.pt.ORCID 0000-0001-5417-6974
Universidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain diseases represent a substantial social and economic burden, currently affecting one in six individuals worldwide. Brain research has been focus of great attention in order to unravel the pathogenesis and complexity of brain diseases at the cellular, molecular, and microenvironmental levels. Due to the intrinsic nature of the brain, the presence of the highly restrictive blood-brain barrier (BBB), and the pathophysiology of most diseases, therapies can hardly be considered successful purely by the administration of one drug to a patient. Apart from improving pharmacokinetic parameters, tailoring biodistribution, and reducing the number of side effects, nanomedicines are able to actively co-target the therapeutics to the brain parenchyma and brain lesions, as well as to achieve the delivery of multiple cargos with therapeutic, diagnostic, and theranostic properties. Among other multivalent effects that can be personalized according to the disease needs, this represents a promising class of novel nanosystems, termed multifunctional nanomedicines. Herein, we review the principal mechanisms of therapeutic resistance of the most prevalent brain diseases, how to overcome this therapeutic resistance through the use of multifunctional nanomedicines that tackle multiple fronts of the disease microenvironment, and the promising therapeutic responses achieved by some of the most cutting-edge multifunctional nanomedicines reported in literature.

Indexed as

Brain DiseasesNanoparticlesDrug Delivery SystemsHumansNanomedicineTissue DistributionBlood–brain barrierBrain diseasesDrug deliveryMultifunctional nanomedicinesTargetingTherapeutic resistance

Identifiers

PMID36344871
OpenAlexW4308550962

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.